Cardinal Health shares rose 3.7% in Thursday trading after the company entered a binding Letter of Intent to extend its existing drug distribution agreement with CVS Health through June 30, 2032. The extension preserves the current scope of distribution services and was accompanied by reaffirmed fiscal 2027 non-GAAP EPS guidance for growth of 13% to 15%, or $12.40 to $12.60, and long-term non-GAAP EPS growth guidance of 12% to 14%. Cardinal Health said it may provide further updates on its first-quarter earnings call on November 5, 2026. The agreement removes uncertainty surrounding a major customer relationship for the pharmaceutical distributor, which also provides specialty, medical, laboratory, home-health and nuclear-pharmacy products and services.